← Eichor
Condition: Ebv Associated Lymphoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Ebv Associated Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma
Phase 1 · 4 location(s) · Baylor College of Medicine · NCT04664179GP350 CAR-T for Relapse/Refractory and Epstein-Barr Virus Infection Associated Lymphoid Neoplasms
Phase 1/Phase 2 · 1 location(s) · Zhimin Zhai · NCT07306156Unrelated Cord Blood Transplantation for EBV-associated Lymphoproliferative Disorders
Phase 2 · 2 location(s) · Fudan University · NCT07381738Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT05389423Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before C
Phase 2 · 7 location(s) · Mayo Clinic · NCT06834373A Registry for People With T-cell Lymphoma
Phase N/A · 26 location(s) · Memorial Sloan Kettering Cancer Center · NCT059781413'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090EBV-AST Cell Injection for EBV-Associated Lymphoproliferative Disorders
Phase 1/Phase 2 · 1 location(s) · Daihong Liu · NCT07450391A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative
Phase 3 · 71 location(s) · Pierre Fabre Medicament · NCT03394365Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Phase N/A · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137643Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT04902443SynKIR-310 for Relapsed/Refractory B-NHL
Phase 1 · 5 location(s) · Verismo Therapeutics · NCT06544265
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.